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1Peripheral artery disease (PAD) is a common disorder that affects >200 million people worldwide.1 PAD is a progres-
sive disease and is associated with a significant reduction in 
patient quality of life. Approximately 10% to 15% of patients 
with claudication progress to critical limb ischemia for ≥5 
years, putting them at risk for amputation.2
Given the lack of data comparing endovascular to open pro-
cedures, the TASC II (Trans-Atlantic Inter-Society Consensus 
Document of Management of Peripheral Arterial Disease) 
update released in 2015 did not provide recommendations 
on procedure type and nor did it recommend specific devices 
when treating PAD patients, also because of the paucity of 
data.3 The first generation methods of endovascular treat-
ment of PAD include percutaneous transluminal angioplasty 
(PTA) and provisional bare metal stent placement. However, 
use of standalone PTA may result in plaque fracture, arterial 
wall stretching, and dissection.4 This can initiate the cycle of 
injury, healing, and negative remodeling, placing the patient at 
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increased risk for restenosis.5 Stent placement can also result 
in unintended negative consequences because leaving a metal 
implant behind can decrease future treatment options or result 
in-stent fractures.6
To address some of these challenges, several published 
clinical studies have investigated the effectiveness of local 
administration of paclitaxel on restenosis after PTA of lesions 
located in the femoropopliteal artery segments.7–10 Results with 
paclitaxel drug-coated balloons (DCB) are promising in TASC 
II A and B lesions,7–10 and patients with long lesions had high 
1-year patency in the SFA-LONG study (Drug Eluting Balloon 
[DEB] and Long Lesions of Superficial Femoral Artery [SFA] 
Ischemic Vascular Disease).11 However, calcified and longer 
lesions remain a challenging subset that is less responsive to 
DCBs, resulting in higher provisional stent rates.12–14
Another second generation device to treat PAD, directional 
atherectomy (DA), removes plaque from the vessel wall, pro-
viding improved luminal gain and plaque modification resulting 
in low rates of bail-out stenting, perforation, and dissection.15
As DA reduces plaque volume, this could potentially facil-
itate a more homogenous delivery of drug to the vessel wall 
and increase drug penetration.16,17
Both technologies were used together in relatively small, 
single-center studies to investigate whether DA and DCB 
could be an effective treatment for lower extremity PAD, and 
in particular, those lesions that are difficult to treat with one 
modality alone.16,18–20 This study aims to expand on these prior 
studies and generate hypotheses for future trials that combines 
treatment with both DA and DCB.
Methods
Study Design
DEFINITIVE AR study (Directional Atherectomy Followed by a 
Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel 
Patency—A Pilot Study of Anti-Restenosis Treatment) is a prospec-
tive, multicenter, randomized controlled pilot trial designed to assess 
and estimate the safety and the effect of treating vessels with DA 
before DCB angioplasty (DA+DCB) as compared with DCB angio-
plasty alone to facilitate the development of future randomized stud-
ies. This study evaluated lesions 7 to 15 cm long in femoropopliteal 
arteries in patients with claudication or rest pain (Rutherford clinical 
category [RCC], 2–4). The rationale for excluding shorter lesions was 
the excellent outcome of DCB angioplasty in these simple lesions in 
former DCB trials and for the upper length limit was to stay with 2 
DCBs maximum guaranteeing full lesion coverage, including DCB 
overlap. Study assessments occurred at baseline, procedure, predis-
charge, 30 days, 6 months, and 1 year after the study procedure. The 
study was conducted in accordance with good clinical practices, ISO 
14155:2011, and applicable laws of all relevant governing bodies. 
Each site’s ethics committee reviewed and approved the study pro-
tocol. All patients signed an informed consent form before any study 
activities took place. Regular monitoring visits were conducted at all 
investigational sites. A clinical events committee composed of inde-
pendent physicians adjudicated all adverse events. Independent core 
laboratories conducted analyses of and adjudicated angiographic im-
ages (SynvaCor, Springfield, Illinois) and duplex ultrasound images 
(VasCore, Massachusetts General Hospital, Boston, Massachusetts). 
An independent data safety monitoring board consisting of a biostat-
istician and physicians not involved in the study reviewed ongoing 
study data. The study was registered on clinicaltrials.gov under the 
identifier NCT01366482.
Patients
Patients from 10 hospitals in Belgium, Germany, Poland, and 
Switzerland were enrolled. Operators were trained in adequate use of 
the atherectomy device and had to submit 25 cases for review before 
they were allowed to participate in the study to guarantee comparable 
skill sets for all operators. Angiographic eligibility was determined 
based on visual estimation by the investigator at the time of the proce-
dure. The key general and angiographic inclusion and exclusion criteria 
are provided in Table 1. Patients with severe calcification in the target 
lesion, defined as fluoroscopic dense circumferential calcification ex-
tending >5 continuous centimeters, were excluded from the randomiza-
tion but were eligible for the nonrandomized (NR) treatment arm after 
meeting all other inclusion criteria and no other exclusion criteria.
Randomization
Patients were enrolled by the investigators and randomly assigned 
to treatment groups after successful passage of the guidewire across 
the target lesion. Block randomization by center was used to assign 
patients in a 1:1 fashion to (1) DA+DCB or (2) DCB alone. Crossover 
to the other treatment arm was not allowed. Patients who were not 
eligible for randomization because of severe calcification were eli-
gible for enrollment in an NR treatment arm of DA+DCB angioplasty 
(NR DA+DCB). Although it was not possible to blind investigators, 
patients, and the angiographic core laboratory to the treatment as-
signment, the duplex ultrasound core laboratory staff and the clinical 
events committee were blinded to the treatment assignment.
WHAT IS KNOWN
• Drug-coated balloons (DCB) angioplasty of femoro-
popliteal TASC II A and B lesions (Trans-Atlantic 
Inter-Society Consensus Document of Management 
of Peripheral Arterial Disease) has shown promis-
ing mid-term results in randomized controlled trials. 
However, depending on lesion complexity, bail-out 
stent placement is indicated in a significant percent-
age of interventions, and patency failures occur in 
particular in calcified lesions.
• Vessel preparation with debulking devices, such as 
directional atherectomy (DA) might improve acute 
and longer-term technical outcomes of DCB angio-
plasty as suggested in small single-center studies.
WHAT THE STUDY ADDS
• Vessel preparation before DCB angioplasty using 
DA for the treatment of femoropopliteal artery dis-
ease is safe.
• Vessel preparation before DCB angioplasty using 
DA significantly improves acute treatment outcomes, 
such as residual stenosis, interventional success, and 
dissection rates.
• Despite significantly better acute outcomes, this un-
derpowered prospective trial did not show superior 
mid-term technical and clinical outcomes for vessel 
preparation before DCB angioplasty using DA as 
compared with plain DCB angioplasty.
• Lesion calcification and lesion length >10 cm were 
identified as potential predictors for superior out-
comes for the combination therapy. A larger-scale 
randomized controlled study focusing on such com-
plex lesion types is warranted.
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Study Devices
DA was performed using the SilverHawk or TurboHawk devic-
es (Medtronic plc, formerly Covidien/ev3, Plymouth, MN). The 
SilverHawk and TurboHawk devices consist of 2 major compo-
nents, the SilverHawk or TurboHawk peripheral catheter and the 
SilverHawk cutter driver. Used together, the system is designed for 
the treatment of de novo and restenotic atherosclerotic lesions located 
in native peripheral arteries. All commercially available SilverHawk 
and TurboHawk catheter models were allowed in the study and the use 
of distal protection devices was left to the discretion of the operators.
The paclitaxel-coated balloon used in the study was the 0.035″ 
Cotavance paclitaxel-coated balloon catheter (Bayer HealthCare, for-
merly MEDRAD, now Medtronic), with the Paccocath coating con-
sisting of a paclitaxel coating concentration of 3 μg/mm2 and Ultravist 
excipient. Paclitaxel promotes the assembly of microtubules from 
tubulin dimers and stabilizes microtubules by preventing depolymer-
ization. This stability results in the inhibition of the normal dynamic 
reorganization of the microtubule network that is essential for vital 
interphase and mitotic cellular functions. It was intended for mechani-
cal/balloon dilatation of stenotic lesions in the iliac and infrainguinal 
arteries while applying paclitaxel to inhibit restenosis. The Cotavance 
catheters received Conformité Européene mark approval on August 4, 
2011 but are no longer commercially available. The Cotavance bal-
loon was chosen because it was the only drug-coated balloon that had 
published proof-of-concept data at the time of trial design.7,8
The use of >1 study balloon per patient was permitted if required 
to cover the entire length of a longer lesion. Predilatation with an 
undersized uncoated angioplasty balloon at low pressure was recom-
mended to allow successful advancement of the DA device or DCB in 
lesions where a DA device or DCB was unable to cross.
Procedures
Treatment of only one target lesion per patient, with 3 cm or less 
between diseased segments requiring treatment, was allowed dur-
ing the index procedure. Iliac artery lesions could be revascularized 
before enrollment, but treatment of any other nontarget lesions was 
not allowed during the index procedure. During the procedure, an-
giographic imaging, including run-off to the ankle/foot, was required 
pretreatment, after predilatation or after DA (if performed), after 
treatment with the DCB, and after adjunctive therapies. In the event 
of a flow-limiting dissection, perforation, or occlusive complication 
(eg, recoil), a prolonged angioplasty with an uncoated balloon (5 
minutes) was suggested. All efforts were made to reduce the need for 
bail-out bare metal stent placement. In cases of suboptimal results 
after prolonged balloon inflation bail-out bare metal stenting was al-
lowed. Adjunctive treatment with cutting balloons or scoring balloons 
was not allowed. Lesion characteristics were analyzed according to 
the angiographic core laboratory assessment.
Additional study assessments included RCC, ankle–brachial index 
(ABI), EuroQOL 5 domains, and walking impairment questionnaire 
(WIQ) at baseline, 30 days, 6 months, and 1 year postprocedure. 
Duplex ultrasound evaluations were required at the predischarge or 
30-day evaluation and at 6 months and 1 year postprocedure. An an-
giogram was required at the 1-year follow-up. Required antiplatelet 
medications included aspirin and clopidogrel preprocedure and post-
procedure (clopidogrel for at least 4 weeks and aspirin indefinitely); 
anticoagulants during the procedure were as indicated by the investi-
gator to maintain appropriate activated clotting times.
End Points and Definitions
The primary outcome was angiographically defined as the target lesion 
percent diameter stenosis at 1 year postprocedure, defined as the narrow-
est point of the target lesion divided by the estimated native vessel diam-
eter at that location as determined by the angiographic core laboratory. 
Secondary outcomes included technical success (defined as ≤30% resid-
ual stenosis following the protocol-defined treatment, before adjunctive 
treatments, at the target lesion as determined by the angiographic core 
laboratory) and major adverse event (MAE) rate at 30 days and 1 year, 
defined as major unplanned amputation of the treated limb, all-cause 
mortality, or clinically driven TLR. Clinically driven TLR (CD-TLR) 
was defined as any reintervention or surgical revascularization involving 
the target lesion in which the patient had ≥70% diameter stenosis and at 
least 2 of the following: worsening RCC, worsening WIQ score, or an 
ABI drop >0.15 from baseline and was assessed at 6 months and 1 year. 
Patency was assessed by duplex ultrasound at 6 months and 1 year with 
rates calculated using both peak systolic velocity ratio (PSVR) ≤3.5 and 
PSVR ≤2.4 at the target lesion with no clinically driven reintervention 
within the target lesion. Measurements at both PSVR values were taken, 
but PSVR values ≤2.4 were reported here because they are more clini-
cally relevant. Core laboratory assessed angiographic patency at 1 year 
was determined in all patients. The protocol defined patency as ≤70% 
stenosis; the more conservative patency of ≤50% stenosis is reported 
here for consistency with other publications. The 1-year angiographic 
analysis also included determination of the target lesion minimum lu-
men diameter and the net luminal gain and difference between baseline 
and 1-year minimum lumen diameter. Changes in RCC, ABI, EuroQOL 
5 domains, and WIQ were also evaluated at 6 months and 1 year in 
comparison with baseline. The ABI evaluation only included patients 
with compressible arteries and baseline ABI <0.9.
Statistical Analysis
All statistical analyses were performed using SAS for Windows (version 
9.2; SAS Institute, Inc, Cary, NC). Descriptive statistics have been used to 
present the data and to summarize the results. Discrete variables are pre-
sented using frequency distributions and cross tabulations. Continuous 
variables are summarized using the number of observations, mean, SD, 
median, 25th quantile, 75th quantile, minimum, and maximum. Unless 
otherwise specified, data for all study patients are presented by treatment 
arm and include all available data for all patients enrolled.
All clinically relevant baseline demographics and procedure char-
acteristics were tabulated for the randomized and NR treatment arms. 
For categorical variables, differences between the randomized arms 
were evaluated with Fisher exact test. For continuous variables, the 
differences were tested using the nonparametric Kruskal–Wallis test.
Table 1.  Key Inclusion and Exclusion Criteria
Key general and angiographic inclusion criteria
  1. RCC of 2–4
  2. Age ≥18 y
  3.  Target lesion of ≥70% de novo stenosis or restenosis or occlusion in 
the SFA and/or popliteal artery.
  4. Had a target lesion length of 7–15 cm.
  5. Had a reference vessel diameter of 4–7 mm.
Key general and angiographic exclusion criteria
  1.  Surgical or endovascular procedure of the target vessel within 14 d 
before the index procedure.
  2. Planned intervention within 30 d after the index procedure.
  3.  Had ≥2 lesions that required treatment in the target limb (not 
including the iliac arteries).
  4. Had a target lesion with an occluded segment ≥5 cm in length.
  5.  Had in-stent restenosis of the target lesion or restenosis of the target 
lesion after previous treatment with a drug-coated balloon.
  6. Had an acute intraluminal thrombus within the target lesion.
  7. Had an aneurysmal target vessel.
  8.  Randomization exclusion criterion: had severe calcification in the 
target lesion (the patients with a severely calcified target lesion 
meeting all other inclusion criteria and no other exclusion criterion 
were eligible for the nonrandomized treatment arm).
RCC indicates Rutherford clinical category.
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For longitudinal outcomes measured at multiple follow-up visits, 
differences between randomized groups over time were evaluated 
with repeated measures analysis. Logistic regression with general-
ized estimating equations was performed for the binary duplex pa-
tency outcome (PSVR ≤2.4), and linear mixed models were used for 
the continuous, functional outcomes. A nonparametric approach was 
performed for EuroQOL 5 domains index, WIQ pain score, and WIQ 
stair climbing score with linear mixed model analysis based on the 
rank-transformed outcomes. For the ordinal Rutherford outcome, 
generalized estimating equations–cumulative logistic regression 
analysis was performed. It is acknowledged that these analyses are 
for exploratory purposes only because the study is not designed to 
have adequate power for such analyses.
For MAE reporting, the outcome analysis is based on patient 
counts. A patient with >1 event was counted only once toward the 
event rate based on the total number of patients with MAEs. Event 
counts are also presented. Kaplan–Meier analysis of the composite 
MAE was also performed with occurrence of first event used as the 
basis for event times. Every patient was treated per the randomiza-
tion, and all analysis was intent-to-treat.
Results
Between August 2011 and May 2013, 121 patients were 
enrolled in the DEFINITIVE AR study, with 102 patients ran-
domized to treatment with DA+DCB (n=48) or DCB (n=54). 
The remaining 19 patients with severely calcified target lesions 
were treated as NR DA+DCB. TurboHawk devices were 
used exclusively in the NR severe calcification arm followed 
by DCB, whereas either SilverHawk (n=18) or TurboHawk 
(n=37) devices were used in the randomized DA+DCB arm.
Patient Characteristics
The mean age was 69.6±8.9 years, and 67.8% (82/121) of 
patients were men (Table 2). All arms of the trial had simi-
lar risk factors and comorbidities, including diabetes mellitus 
and chronic kidney disease. No baseline patient characteristics 
were statistically significantly different between randomized 
treatment groups. At study completion, 100% (121/121) of 
patients completed the predischarge visit, 95.0% (115/121) the 
30-day visit, 90.9% (110/121) the 6-month visit, and 88.4% 
(107/121) the 1-year visit (Figure). The 1-year follow-up 
completion was 85.4% for the DA+DCB group (3 withdrew, 2 
were lost to follow-up, and 2 died), 92.6% for the DCB group 
(3 withdrew and 1 died), and 84.2% for the NR DA+DCB 
group (1 withdrew, 1 was lost-to-follow-up, and 1 died).
Lesion Characteristics
The mean lesion length as measured by the angiographic 
core laboratory for all enrolled patients was 106.3±43.9 mm 
(Table 3). The lesion lengths were longer in the DA+DCB 
group in comparison with the DCB group (112.3±40.3 mm 
versus 96.6±40.9 mm; P=0.05). The mean lesion length in the 
NR DA+DCB group was longer than both randomized groups 
(118.7±56.2 mm). Calcium was present in most lesions 
treated (70.8% of DA+DCB, 74.1% of DCB, and 100% of 
NR DA+DCB) as determined by angiography films analyzed 
by the core laboratory. Severe calcification was found in the 
NR DA+DCB group (94.7%) and in the randomized arms 
(25.0% of DA+DCB group versus 18.5% of DCB group). The 
mean percent diameter stenosis at baseline was 81.9±16.0% 
for the DA+DCB group, 84.9±14.9% for the DCB group, 
and 87.9±11.3% for the NR DA+DCB group (Table 3). The 
majority of lesions were de novo in all arms (89.6% in the 
DA+DCB group, 92.6% in the DCB group, and 78.9% in the 
NR DA+DCB group). There was no significant difference 
between the study arms with regards to lesion calcification, 
severe calcification, mean percent diameter stenosis, or lesion 
de novo status.
Procedural Outcomes
Technical success (≤30% residual stenosis following protocol-
assigned treatment, before adjunctive treatments) at the target 
lesion was 89.6% for the DA+DCB group versus 64.2% for the 
DCB group (P=0.004). Technical success in the NR DA+DCB 
group was 84.2%. Use of the SpiderFX filter for distal embolic 
protection was reported in patients treated with atherectomy; 
85.4% of DA+DCB patients and 100% of NR DA+DCB 
patients had a SpiderFX filter in place during the procedure.
Of the randomized patients, 16.7% of the DA+DCB 
patients received predilation before use of the DA device in 
comparison with 74.1% in the DCB-only arm. Predilatation 
occurred in 31.6% of patients enrolled in the NR DA+DCB 
arm. Adjunctive therapies after DA included bail-out stenting 
and postdilation. In the randomized DA+DCB arm, 6.3% of 
patients received adjunctive therapy, compared with 37.0% in 
the DCB alone arm (P<0.0001). In the NR DA+DCB group, 
5.3% of patients received adjunctive therapy. Bail-out bare 
metal stenting was performed for 2 DCB patients (3.7%) and 1 
NR DA+DCB patient (5.3%), and postdilatation PTA was per-
formed for 3 DA+DCB patients (6.3%) and 18 DCB patients 
(33.3%; P=0.001).
The most common procedural complications (Table 4) 
were grade C/D dissections, which occurred more frequently 
in the DCB arm (n=10; 18.5%) than in the DA+DCB group 
(n=1; 2.1%; P=0.01). No relevant dissections occurred in the 
NR DA+DCB group. In the DA+DCB cohort, there were 2 
clinically significant distal embolization events requiring 
endovascular interventions and 1 distal embolization event 
that was not clinically significant. Additionally, 2 perforations 
(4.2%) occurred in the DA+DCB group with none in the DCB 
group (P=0.22). Both perforations were successfully treated 
with prolonged PTA; however, per protocol, treatment with 
DCB was not allowed after the perforations.
Angiographic and Duplex Sonographic 1-Year 
Outcomes
The 1-year primary end point of angiographic target lesion 
percent diameter stenosis was 33.6±17.7% (n=33) for the 
DA+DCB group versus 36.4±17.6% (n=39) for the DCB 
group (P=0.48) and 55.0±30.5% (n=14) for the NR DA +DCB 
group (Table 5). For lesions ≥10 cm, the 1-year mean percent 
diameter stenosis was 31.1±11.9% for the DA+DCB group 
(n=20) and 36.6±13.7% for the DCB group (n=16). No sig-
nificant differences were found in the minimum lumen diam-
eter and net lumen gain at 1 year (Table 5; P=0.48 and 0.62).
The 1-year angiographic primary patency was 82.4% 
(28/34) for the DA+DCB group versus 71.8% (28/39) for the 
DCB group (P=0.41) and 50.0% (7/14) for the patients in the 
NR DA+DCB cohort. Patency was also assessed via duplex 
ultrasonography (DUS). The DUS patency rate at 6 months 
and 1 year, respectively, was 95.0% (38/40) and 84.6% 
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(33/39) for the DA+DCB group, 88.9% (40/45) and 81.3% 
(39/48) for the DCB group (P=0.44 at 6 months and P=0.78 
at 1 year), and 86.7% (13/15) and 68.8% (11/16) for the NR 
DA+DCB group. Using all available DUS patency data at 
6 and 12 months, no significant differences over time were 
observed between randomized groups (generalized estimating 
equations logistic regression P=0.42). The patency rate using 
PSVR ≤3.5 at 6 months and 1 year, respectively, was 95.0% 
(38/40) and 87.2% (34/39) for the DA+DCB group, 93.3% 
(42/45) and 89.6% (43/48) for the DCB-only group (P>0.99 at 
6 months and P=0.75 at 1 year), and 86.7% (13/15) and 75.0% 
(12/16) for the NR DA+DCB group.
Table 2. Baseline Demographics, Risk Factors, and Medical History
 
Nonrandomized Randomized
All PatientsDA+DCB DA+DCB DCB Only P Value*
Patient Characteristics
  Age, y    0.44  
   Mean±SD 69.7±8.9 (19) 70.1±9.7 (48) 69.0±8.2 (54)  69.6±8.9 (121)
   Median (Q1–Q3) 68.0 (66.0–76.0) 70.5 (62.5–78.5) 69.0 (64.0–75.0)  70.0 (64.0–76.0)
   Range (min–max) (50.0–86.0) (48.0–86.0) (52.0–85.0)  (48.0–86.0)
  Men 73.7% (14/19) 64.6% (31/48) 68.5% (37/54) 0.68 67.8% (82/121)
  Race    >0.99  
   White 94.4% (17/18) 100.0% (47/47) 98.1% (53/54) … 98.3% (117/119)
   Other 5.6% (1/18) 0.0% (0/47) 1.9% (1/54) … 1.7% (2/119)
Medical history    …  
  Angina 26.3% (5/19) 4.2% (2/48) 9.3% (5/54) 0.44 9.9% (12/121)
  Congestive heart failure 5.3% (1/19) 2.1% (1/48) 5.6% (3/54) 0.62 4.1% (5/121)
  CAD 73.7% (14/19) 45.8% (22/48) 38.9% (21/54) 0.55 47.1% (57/121)
  Stroke 5.3% (1/19) 8.3% (4/48) 7.4% (4/54) >0.99 7.4% (9/121)
  TIA 5.3% (1/19) 6.3% (3/48) 7.4% (4/54) >0.99 6.6% (8/121)
  MI 36.8% (7/19) 18.8% (9/48) 25.9% (14/54) 0.48 24.8% (30/121)
  CABG or PCI 63.2% (12/19) 37.5% (18/48) 33.3% (18/54) 0.68 39.7% (48/121)
  Prior intervention of the target vessel 42.1% (8/19) 29.2% (14/48) 18.5% (10/54) 0.25 26.4% (32/121)
Risk factors    …  
  Smoking    0.31  
   Current smoker 10.5% (2/19) 37.5% (18/48) 40.7% (22/54) … 34.7% (42/121)
   Past smoker 26.3% (5/19) 12.5% (6/48) 22.2% (12/54) … 19.0% (23/121)
   Never smoker 63.2% (12/19) 50.0% (24/48) 37.0% (20/54) … 46.3% (56/121)
  Diabetes mellitus 26.3% (5/19) 27.1% (13/48) 35.2% (19/54) 0.40 30.6% (37/121)
   Type I 0.0% (0/19) 0.0% (0/48) 7.4% (4/54) … 3.3% (4/121)
   Type II 26.3% (5/19) 27.1% (13/48) 27.8% (15/54) … 27.3% (33/121)
  Hypertension 84.2% (16/19) 87.5% (42/48) 81.5% (44/54) 0.43 84.3% (102/121)
  Hyperlipidemia 73.7% (14/19) 70.8% (34/48) 68.5% (37/54) 0.83 70.2% (85/121)
  Chronic kidney disease 15.8% (3/19) 12.5% (6/48) 14.8% (8/54) 0.78 14.0% (17/121)
  End stage renal disease 0.0% (0/19) 0.0% (0/48) 0.0% (0/54) … 0.0% (0/121)
Clinical characteristics    …  
  RCC    0.91  
  2=Moderate claudication 15.8% (3/19) 27.1% (13/48) 24.1% (13/54) … 24.0% (29/121)
  3=Severe claudication 84.2% (16/19) 70.8% (34/48) 74.1% (40/54) … 74.4% (90/121)
  4=Ischemic rest pain 0.0% (0/19) 2.1% (1/48) 1.9% (1/54) … 1.7% (2/121)
CABG indicates coronary artery bypass graft; CAD, coronary arterial disease; DA, directional atherectomy; DCB, drug-coated balloon; MI, myocardial 
infarction; PCI, percutaneous coronary intervention; RCC, Rutherford clinical category; and TIA, transient ischemic attack.
*P values compare randomized arms only.
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An ad hoc angiographic analysis of patency in lesions 
>10 cm demonstrated a trend toward a potential advantage 
to DA+DCB treatment of 95.0% for DA+DCB (n=20) versus 
68.8% for DCB (n=16). However, this trend was less evident 
in the 1-year duplex ultrasound patency analysis: (PSVR≤2.4) 
of 95.7% for DA+DCB (n=23) versus 85.0% for DCB (n=20). 
A trend toward achieving better 12-month patency was seen 
related to achieving ≤30% residual stenosis post-DA before 
DCB treatment. For lesions in the DA+DCB group that achieved 
≤30% residual stenosis after DA, angiographic 1-year patency 
was 88.2% (n=17) and DUS 1-year patency (PSVR≤2.4) was 
84.2% (n=19) in comparison with 68.8% (n=16) and 77.8% 
(n=18) for lesions with >30% residual stenosis after DA.
The data also suggest a potential advantage of DA+DCB 
for severely calcified lesions, but the number of lesions was too 
small to show statistical significance. All lesions were reclas-
sified as either severely calcified or not severely calcified by 
the core laboratory, regardless of their inclusion in either the 
DA+DCB, DCB only, or NR DA+ DCB arm. Based on this 
classification, 1-year patency by angiography of severely calci-
fied lesions treated with both DA and DCB was 58.3% (14/24), 
and patency of severely calcified lesions treated with DCB 
alone was 42.9% (3/7). For this same grouping of patients, DUS 
patency at 1 year was 70.4% (19/27) for patients treated by DA 
and DCB versus 62.5% (5/8) for patients treated by DCB alone.
Major Adverse Events
MAEs were defined as major unplanned amputations of the 
treated limb, all-cause mortality, or CD-TLR. A total of 18 
MAEs were reported and adjudicated by the clinical events 
committee, including 4 deaths and 14 CD-TLRs. No major 
amputation was observed. The 30-day freedom from MAE 
rate determined by Kaplan–Meier was 97.9% for DA+DCB, 
98.1% for DCB, and 100.0% for NR DA+DCB. The 30-day 
MAEs included a single CD-TLR in each of the randomized 
study arms. The 1-year freedom from MAE rate determined by 
Kaplan–Meier was 89.3% for DA+DCB versus 90.0% for DCB 
(P=0.86) and 94.4% for NR DA+DCB. The 1-year MAE events 
included 2 deaths and 3 CD-TLRs after DA+DCB, 1 death and 
5 CD-TLRs in the DCB arm, and 1 death in the NR DA+DCB 
group. Differences in the MAE rates at both 30 days and 1 year 
were not statistically significant. No amputations of the treated 
limb occurred. None of the 4 deaths were attributed to the study 
devices or procedure (heart failure/stroke, acute coronary syn-
drome, respiratory failure, and neoplastic disorder).
At 6 months, 4.7% (2/43) of the DA+DCB group had a 
CD-TLR compared with 3.9% (2/51) of the DCB group. At 1 
year, 7.3% (3/41) of the DA+DCB group had a TLR compared 
with 8.0% (4/50) of DCB group. No CD-TLR occurred in the 
NR DA+DCB group. The Kaplan–Meier-estimated freedom 
from CD-TLR rates were 95.7% versus 96.3% at 6 months 
and 93.2% versus 91.9% at 1 year for the DA+DCB and DCB 
groups, respectively, and 100% at 6 months and 1 year for the 
NR DA+DCB group.
Functional Outcomes
No significant differences in functional outcomes were observed 
between the randomized groups (Table 6). The majority of 
patients had an improvement of at least 1 RCC at 6 months 
(97.7% DA+DCB, 90.2% DCB, and 87.5% NR DA+DCB) 
and at 1 year (85.4% DA+DCB, 93.9% DCB, and 81.3% NR 
DA+DCB) in comparison with baseline. Only one patient (DCB 
group) had a worsening of RCC at 6 months. Similarly, improve-
ment in ABI for patients with compressible arteries and base-
line ABI<0.9 were observed for 85.2% DA+DCB, 85.7% DCB, 
and 88.9% NR DA+DCB of patients at 6 months and 89.3% 
DA+DCB, 88.6% DCB, and 88.9% NR DA+DCB of patients 
at 1 year. Improvements in WIQ and EuroQOL 5 domain scores 
were also seen in all groups at 6 months and 1 year.
Discussion
DEFINITIVE AR was the first prospective, multicenter study 
designed to estimate the effect of treating femoropopliteal 
arteries with DA before a DCB. Because this was a pilot study 
designed to facilitate development of additional studies, differ-
ences in outcomes show only nonsignificant trends because of 
lack of cohort size to yield statistical power. Major findings of 
DEFINITIVE AR include the safety of the combination of DA 
with DCB ≤1-year follow-up and potential patency benefits for 
both longer and severely calcified lesions. This is especially rel-
evant to the field because using PTA alone to treat both longer 
and calcified lesions remains a challenge. DA is well suited to 
remove plaque and to potentially reduce vessel recoil, reduce 
the rate of severe dissections, and facilitate a more homogenous 
drug application and diffusion into the vessel wall layers.15,21 
Combining a device that reduces plaque volume with one that 
reduces neointimal hyperplasia (DA+DCB) may be an even 
more effective treatment of lower extremity PAD.
DA that resulted in <30% stenosis was associated in a post 
hoc analysis with a higher 1-year patency rate whether patency 
was measured by angiography or duplex. Lesions with ≤30% 
residual stenosis after DA resulting in lumen gain achieved 
angiographic patency of 88.2% and duplex patency of 84.2%, 
whereas lesions with >30% residual stenosis achieved angio-
graphic patency of 68.8% and duplex patency of 77.8%. In 
the randomized DA+DCB arm, no stents were required, and 
Figure. Study profile/compliance. DA indicates directional ather-
ectomy; DCB, drug-coated balloon; and NR, nonrandomized.
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only one lesion required stenting in the registry arm, confirm-
ing the findings of the DEFINITIVE LE (Determination of 
Effectiveness of the SilverHawk® Peripheral Plaque Excision 
System (SilverHawk Device) for the Treatment of Infrainguinal 
Vessels / Lower Extremities) and the DEFINITIVE calcium 
studies with stent rates after DA of 3.0% and 4.1%, respec-
tively.15,21 All efforts were made to reduce the need for bail-out 
bare metal stent placement. Because the use of reentry devices 
was an exclusion criterion, most of the occlusions were crossed 
intraluminally, potentially resulting in a reduced likelihood of 
multiple dissection planes, which usually result in bail-out 
stent placement, potentially explaining the low overall bail-out 
stent rate in the present study.
The 1-year DUS patency rates of 84.6% for the random-
ized DA+DCB arm in DEFINITIVE AR confirms the out-
come of a small prospective, single-center study conducted by 
Cioppa et al17 of patients with severely calcified femoropopli-
teal lesions (defined as fluoroscopic calcification on both sides 
of vessel wall >1 cm in length). Patients were treated with 
DA until a <30% residual stenosis was achieved, as confirmed 
by intravascular ultrasound and angiography, after by DCB 
(IN.PACT Admiral, Medtronic, Inc). In their study, the bail-
out stent rate was 6.5%, the 1-year duplex-derived primary 
patency rate was 90%, and the freedom from MAEs was 87%. 
Both this study and the current study highlight the potential 
value of DA+DCB in calcified lesions.
Table 3. Angiographic Core Laboratory Reported Lesion Characteristics
 
Lesion Characteristics
Nonrandomized Randomized All Patients
DA+DCB DA+DCB DCB Only P Value*  
Target lesion location    0.94  
  Proximal SFA 10.5% (2/19) 4.2% (2/48) 3.7% (2/54) … 5.0% (6/121)
  Mid SFA 63.2% (12/19) 58.3% (28/48) 55.6% (30/54) … 57.9% (70/121)
  Distal SFA and popliteal 26.3% (5/19) 37.5% (18/48) 40.7% (22/54)  37.2% (45/121)
Lesion length, mm    0.05  
  Mean±SD 118.7±56.2 (19) 112.3±40.3 (48) 96.6±40.9 (54)  106.3±43.9 (121)
  Median (Q1–Q3) 120.1 (75.3–165.6) 107.2 (87.8–139.2) 94.1 (73.9–119.0)  103.1 (83.4–130.1)
  Range (min–max) (20.8–223.7) (19.5–220.0) (12.6–189.6)  (12.6–223.7)
Diameter stenosis, %    0.35  
  Mean±SD 87.9±11.3 (19) 81.9±16.0 (48) 84.9±14.9 (54)  84.2±14.9 (121)
  Median (Q1–Q3) 89.0 (81.0–100.0) 85.5 (70.5–97.5) 87.5 (77.0–100.0)  87.0 (76.0–100.0)
  Range (min–max) (55.0–100.0) (46.0–100.0) (50.0–100.0)  (46.0–100.0)
Occlusion 26.3% (5/19) 25.0% (12/48) 33.3% (18/54) 0.39 28.9% (35/121)
De novo (site reported) 78.9% (15/19) 89.6% (43/48) 92.6% (50/54) 0.73 89.3% (108/121)
Reference vessel diameter, mm    0.48  
  Mean±SD 5.1±0.9 (19) 4.9±1.1 (48) 4.9±0.9 (54)  4.9±1.0 (121)
  Median (Q1–Q3) 5.2 (4.3–5.5) 4.6 (4.2–5.5) 4.7 (4.4–5.5)  4.7 (4.3–5.5)
  Range (min–max) (3.6–6.8) (2.4–7.6) (2.4–7.0)  (2.4–7.6)
Minimum lumen diameter, mm    0.34  
  Mean±SD 0.7±0.7 (19) 1.0±0.9 (48) 0.8±0.8 (54)  0.8±0.8 (121)
  Median (Q1–Q3) 0.6 (0.0–1.1) 0.7 (0.1–1.4) 0.7 (0.0–1.1)  0.7 (0.0–1.2)
  Range (min–max) (0.0–2.7) (0.0–3.4) (0.0–3.4)  (0.0–3.4)
Calcification 100.0% (19/19) 70.8% (34/48) 74.1% (40/54) 0.82 76.9% (93/121)
Severe calcification 94.7% (18/19) 25.0% (12/48) 18.5% (10/54) 0.48 33.1% (40/121)
TASC    0.30  
  A 31.6% (6/19) 33.3% (16/48) 48.1% (26/54) … 39.7% (48/121)
  B 42.1% (8/19) 56.3% (27/48) 42.6% (23/54) … 47.9% (58/121)
  C 26.3% (5/19) 10.4% (5/48) 9.3% (5/54) … 12.4% (15/121)
  D 0.0% (0/19) 0.0% (0/48) 0.0% (0/54) … 0.0% (0/121)
DA indicates directional atherectomy; DCB, drug-coated balloon; and TASC, Trans-Atlantic Inter-Society Consensus Document of Management of Peripheral 
Arterial Disease.
*P value compares randomized arms only; values are expressed as a percentage or as a mean±SD (N).
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Stavroulakis et al18 measured patency, procedural success, 
morbidity, and mortality after treatment of popliteal lesions 
with a combined therapy of DA and DCB. In their single-arm 
study of 21 patients, 1-year primary patency was 95% as esti-
mated by Kaplan–Meier.
The outcome of the DCB-only arm of the present study 
confirms the performance of the DCB arms of the historical 
THUNDER trial (Local Taxan With Short Time Contact for 
Reduction of Restenosis in Distal Arteries) and FEMPAC 
trial (Femoral Paclitaxel) where similar DCBs were used.7,8 
Because of the excellent performance of DCB alone in TASC 
II A and B femoropopliteal lesions—provided they are not 
severely calcified—the DA+DCB strategy should be reserved 
to more complex lesions.
Currently, there is no published economic analysis of the 
use of DA+DCB. Panaich et al22 reported that although ather-
ectomy utilization was predictive of lower in-hospital mortal-
ity, lower amputation rates, and lower complication rates, it 
Table 4. Procedural Complications
 Nonrandomized Randomized
Complication DA+DCB DA+DCB DCB Only P Value*
Arterial perforation 0% (0/19) 4.2% (2/48) 0% (0/54) 0.22
Arteriovenous fistula 0% (0/19) 6.3% (3/48) 11.1% (6/54) 0.49
Dissection—grade C/D or greater 0% (0/19) 2.1% (1/48) 18.5% (10/54) 0.009
Distal embolism (clinically significant) 5.3% (1/19) 4.2% (2/48) 0% (0/54) 0.22
Distal embolism (not clinically significant) 0% (0/19) 2.1% (1/48) 0% (0/54) 0.47
Aneurysm 0% (0/19) 0% (0/48) 0% (0/54) …
Pseudoaneurysm 5.3% (1/19) 6.3% (3/48) 0% (0/54) 0.10
Total† 5.3% (1/19) [2] 22.9% (11/48) [12] 25.9% (14/54) [16] 0.82
Individual event rates do not sum to the total because patients may experience >1 event type. DA indicates directional atherectomy; and DCB, 
drug-coated balloon.
*P value compares randomized arms only.
†Percentage of patients (n/n patients affected) [total number of events].
Table 5. Vessel Characteristics and Results
Nonrandomized Randomized
DA+DCB DA+DCB DCB Only
MLD, mm    
  Mean±SD (N), baseline 0.67±0.66 (19) 0.96±0.94 (48) 0.78±0.81 (54)
  Mean±SD (N), 1 y 2.39±1.65 (14) 3.52±1.24 (32) 3.33±1.09 (39)
  Median (Q1–Q3), baseline 0.6 (0.0–1.1) 0.7 (0.1–1.4) 0.7 (0.0–1.1)
  Median (Q1–Q3), 1 y 2.5 (0.4–4.2) 3.5 (3.0–4.1) 3.4 (2.5–4.1)
  Range (min–max), baseline (0.0–2.7) (0.0–3.4) (0.0–3.4)
  Range (min–max), 1 y (0.0–4.4) (0.0–5.6) (0.0–5.4)
Net Lumen Gain at 1 y, mm    
  Mean±SD (N) 1.60±1.68 (14) 2.38±1.55 (32) 2.57±1.16 (39)
  Median (Q1–Q3) 2.0 (−0.4 to 3.0) 2.4 (1.3–3.6) 2.8 (1.8–3.4)
  Range (min–max) (−1.1 to 3.7) (−0.9 to 5.6) (−1.1 to 4.4)
Percent diameter stenosis    
  Mean±SD (N), baseline 87.9±11.3% (19) 81.9±16.0% (48) 84.2±14.9% (54)
  Mean±SD (N), 1 y 55.0±30.5% (14) 33.6±17.7% (33) 36.4±17.6% (39)
  Median (Q1, Q3), baseline 89.0 (81.0–100.0) 85.5 (70.5–97.5) 87.5 (77.0–100.0)
  Median (Q1, Q3), 1 y 50.0 (26.0–91.0) 30.0 (25.0–36.0) 32.0 (23.0–47.0)
Primary patency via angiography 50.0% (7/14) 82.4% (28/34) 71.8% (28/39)
Primary patency via ultrasound at 6 mo (PSVR ≤2.4)* 86.7% (13/15) 95.0% (38/40) 88.9% (40/45)
Primary patency via ultrasound at 1 y (PSVR ≤2.4) 68.8% (11/16) 84.6% (33/39) 81.3% (39/48)
DA indicates directional atherectomy; DCB, drug-coated balloon; MLD, minimum lumen diameter; and PSVR, peak systolic velocity ratio.
*Duplex ultrasound.
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Table 6. Functional Outcomes
 Baseline 6 mo 1 y P Value*
RCC    0.72
  DA+DCB (mean) 2.8±0.5 (48) 0.5±0.7 (43) 0.9±1.0 (41)  
  DA+DCB (median, Q1–Q3) 3.0 (2.0–3.0) 0.0 (0.0–1.0) 1.0 (0.0–1.0)  
  DCB (mean) 2.8±0.5 (54) 0.8±0.9 (51) 0.7±0.9 (49)  
  DCB (median, Q1–Q3) 3.0 (3.0–3.0) 1.0 (0.0–1.0) 0.0 (0.0–1.0)  
  NR DA+DCB (mean) 2.8±0.4 (19) 0.8±1.1 (16) 1.3±1.1 (16)  
  NR DA+ DCB (median, Q1–Q3) 3.0 (3.0–3.0) 0.0 (0.0–1.5) 1.0 (0.5–2.0)  
ABI    0.74
  DA+DCB (mean) 0.7±0.16 (36) 0.9±0.19 (33) 0.9±0.14 (32)  
  DA+DCB (median, Q1–Q3) 0.7 (0.5–0.7) 0.9 (0.8–1.0) 0.9 (0.8–1.0)  
  DCB (mean) 0.7±0.22 (42) 0.9±0.15 (40) 0.90±0.19 (41)  
  DCB (median, Q1–Q3) 0.7 (0.5–0.8) 0.9 (0.8–1.0) 0.9 (0.8–1.0)  
  NR DA+DCB (mean) 0.7±0.16 (15) 0.9±0.23 (10) 0.9±0.27 (11)  
  NR DA+ DCB (median, Q1–Q3) 0.6 (0.5–0.8) 0.9 (0.8–1.0) 0.9 (0.7–1.0)  
WIQ–pain score, %    0.60
  DA+DCB (mean) 38.5±29.2 (48) 93.0±14.8 (43) 80.5±27.7 (41)  
  DA+DCB (median, Q1–Q3) 25.0 (25.0–50.0) 100.0 (100.0–100.0) 100.0 (50.0–100.0)  
  DCB (mean) 44.9±32.0 (54) 87.7±24.7 (51) 80.5±30.4 (50)  
  DCB (median, Q1–Q3) 25.0 (25.0–75.0) 100.0 (100.0–100.0) 100.0 (50.0–100.0)  
  NR DA+DCB (mean) 28.9±26.7 (19) 96.7±12.9 (15) 78.1±25.6 (16)  
  NR DA+DCB (median, Q1–Q3) 25.0 (25.0–25.0) 100.0 (100.0–100.0) 87.5 (50.0–100.0)  
WIQ–walking distance score, %    0.67
  DA+DCB (mean) 33.7±27.8 (47) 81.1±32.6 (43) 71.9±36.6 (41)  
  DA+DCB (median, Q1–Q3) 30.8 (8.1–49.8) 100.0 (73.2–100.0) 90.0 (43.1–100.0)  
  DCB (mean) 26.6±20.9 (53) 78.3±33.3 (51) 76.4±34.7 (50)  
  DCB (median, Q1–Q3) 25.2 (6.3–40.8) 100.0 (55.4–100.0) 100.0 (62.1–100.0)  
  NR DA+DCB (mean) 24.1±24.2 (19) 96.1±12.5 (15) 77.1±34.6 (16)  
  NR DA+DCB (median, Q1–Q3) 11.8 (5.8–36.4) 100.0 (100.0–100.0) 100.0 (57.0–100.0)  
WIQ–walking speed score, %    0.60
  DA+DCB (mean) 30.4±20.2 (47) 59.9±32.1 (43) 50.0±30.8 (41)  
  DA+DCB (median, Q1–Q3) 28.3 (17.4–43.5) 56.5 (43.5–100) 50.0 (28.3–67.4)  
  DCB (mean) 28.6±21.1 (54) 52.2±29.8 (51) 52.5±30.9 (49)  
  DCB (median, Q1–Q3) 28.8 (10.9–43.5) 56.5 (26.1–65.2) 56.5 (30.4–78.3)  
  NR DA+DCB (mean) 21.0±19.1 (19) 60.7±27.1 (15) 53.8±30.8 (16)  
  NR DA+DCB (median, Q1–Q3) 10.9 (6.5–35.9) 56.5 (43.5–100.0) 38.0 (31.5–85.9)  
WIQ–stair climbing score, %    0.77
  DA+DCB (mean) 70.2±31.1 (47) 89.0±26.9 (43) 79.3±34.9 (41)  
  DA+DCB (median, Q1–Q3) 75.0 (50.0–100.0) 100.0 (100.0–100.0) 100.0 (75.0–100.0)  
  DCB (mean) 74.1±28.6 (53) 86.8±28.0 (51) 85.5±26.3 (50)  
  DCB (median, Q1–Q3) 75.0 (50.0–100.0) 100.0 (100.0–100.0) 100.0 (75.0–100.0)  
  NR DA+DCB (mean) 60.5±33.7 (19) 100.0±0.0 (15) 87.5±18.3 (16)  
  NR DA+DCB (median, Q1–Q3) 75.0 (25.0–100.0) 100.0 (100.0–100.0) 100.0 (75.0–100.0)  
(Continued )
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was also associated with higher cost of procedures in 2012 
(although authors noted the population of patients treated by 
atherectomy tended to have more diffuse disease and comor-
bidities). Pietzsch et al23 concluded that DCB technology is 
associated with lower revascularization rates and cost savings 
for both the United States and Germany. The recently published 
DCB budget impact model goes so far as to assert that “DCBs 
offer the highest clinical and economic value.”24 Considering 
worldwide limited financial resources for healthcare systems, 
cost-effectiveness analyses should be implemented into future 
larger-scale randomized controlled trials evaluating the true 
benefit of combining DA+DCB. An ideal follow-up study 
would include an increased number of patients, longer-term 
follow-up, and focus on calcified lesions.
Limitations
The study was not sufficiently powered as a pivotal study 
to draw final conclusions about the impact of DA for lesion 
preparation before DCB angioplasty in femoropopliteal inter-
ventions. Additionally, there was a significant difference in 
balloon pre- and postdilatation between trial arms. Finally, the 
mean lesion length in the DA+DCB group was longer than 
the DCB group, potentially preventing detection of a signifi-
cant difference between the groups. A follow-up study should 
include an increased number of patients, a focus on calcified 
lesions, and patients should be followed up for a longer period 
of time. Moreover, the outcomes cannot be extrapolated to the 
impact of other atherectomy or DCB technologies, or in other 
lesion locations.
Conclusions
Although DCB has been shown to increase primary patency 
rates in TASC II A and B femoropopliteal lesions, challenging 
subsets remain: severely calcified lesions do not experience the 
same patency.12 For the treatment of femoropopliteal lesions, 
vessel preparation with DA before DCB angioplasty seems to 
be safe in mid-term follow-up and might have benefits in more 
challenging lesion subsets that are at higher risk for acute and 
chronic technical treatment failure of PTA, including DCB 
angioplasty, such as severely calcified lesions. In this study, 
treatment with DA+DCB resulted in both increased techni-
cal success and fewer flow-limiting dissections compared 
with treatment with DCB alone. A sufficiently powered ran-
domized controlled trial is needed to further characterize the 
potential benefits of DA+DCB.
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